TMCnet News

Research and Markets: PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
[April 09, 2015]

Research and Markets: PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023


Research and Markets (http://www.researchandmarkets.com/research/l9c9gj/pharmapoint) has announced the addition of the "PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023" report to their offering.

HER2-Negative Breast Cancer Treatment Market Value to Rise More than Fourfold by 2023

The market value for HER2-negative breast cancer therapeutics will increase more than fourfold, from $1.45 billion in 2013 to an estimated $6.12 billion by 2023, as the treatment landscape shifts from chemotherapy to hormone therapies, according to research and consulting firm The authors.

The report states that this growth, which will occur across eight major markets (the US, France, Germany, Italy, Spain, UK, Japan and China) at a Compound Annual Growth Rate (CAGR) of 15.5%, will largely be driven by the launch of several premium-priced products and their rapid acceptance and reimbursement across various settings.

Shabaaz Ali, MSc, The authors's Analyst covering Oncology, says that three of the most exciting classes of premium-priced products due to launch during the forecast period include the CDK4/6 and PI3K inhibitors in te hormone receptor-positive (HR+) setting and PARP inhibitors in the BRCA mutation positive subset of the triple negative breast cancer (TNBC) setting. These drugs are expected to account for $5.1 billion and 84% of global HER2-negative breast cancer treatment sales by 2023.



Ali explains: By the end of the forecast period, CDK4/6 and PI3K inhibitors will account for $3.6 billion and 79% of global sales in the HR+ setting, while PARP inhibitors will account for $1.02 billion and 94% of the market for TNBC treatment.

We believe Pfizer will dominate the HR+ setting, largely as a result of palbociclib being the first CDK 4/6 inhibitor to market, which will be accelerated by the US Food and Drug Administration's breakthrough therapy designation.


The analyst adds that AstraZeneca will become the market leader in TNBC treatment with the launch of its PARP inhibitor, Lynparza, despite the drug not being the first to market in this class.

Ali continues: AstraZeneca's position as a pharmaceutical giant with a strong portfolio of now-generic hormonal therapies will allow it to dominate this setting, with 79% of peak-year Lynparza sales coming from the adjuvant setting.

However, it should be noted that although AstraZeneca will be the clear market leader in the TNBC setting by 2023, Lynparza will only be used in the niche population of patients with a BRCA-positive tumor.

This report provides annualized HER2-negative breast cancer therapeutics market revenue, cost of therapy, and treatment usage patterns in 15 patient segments, forecast from 2013 to 2023 across eight major markets, namely the US, France, Germany, Italy, Spain, UK, Japan and China. Key topics covered include strategic competitor assessment, market characterization, unmet needs, research and development strategies, pipeline analysis and clinical trial design.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Need and Opportunity

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

Companies Mentioned

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Novartis/GlaxoSmithKline

For more information visit http://www.researchandmarkets.com/research/l9c9gj/pharmapoint


[ Back To TMCnet.com's Homepage ]